ReviewZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026
[Acute
Review in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hemochromatosis (HC) is a disorder of iron metabolism characterized by excessive iron deposition in the body due to genetic mutations or secondary factors, leading to organ damage and dysfunction, particularly in the liver, heart, and pancreas. This disease is relatively rare in China, and cases of hemochromatosis occurring on the basis of post-hepatitis B‑related cirrhosis and subsequently inducing liver failure are even rarer. In October 2022, Guangdong Provincial Hospital of Traditional Chinese Medicine Hainan Hospital admitted a middle‑aged male patient with post-hepatitis B cirrhosis complicated by hemochromatosis, who subsequently developed acute-on-chronic liver failure (ACLF). The patient experienced a sudden and severe deterioration in liver function on the background of long-standing hepatitis B-related cirrhosis, meeting the diagnostic criteria for ACLF. Notably, liver failure occurred despite effective suppression of hepatitis B virus DNA replication, suggesting that non-viral factors contributed to the pathogenesis of liver failure. The diagnosis of hepatic hemochromatosis was ultimately confirmed by liver biopsy. Based on this case and a review of the literature, we propose that in patients with chronic liver disease, especially those presenting with unexplained acute deterioration of liver function or markedly elevated serum ferritin levels, hemochromatosis should be included in the routine differential diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.